Pfizer reported second-quarter financial results that surpassed Wall Street earnings estimates, driven by strong sales across its non-COVID product portfolio, even as the pharmaceutical giant recorded a net loss due to a substantial asset writedown. According to company financial statements released on July 30, 2024, Pfizer posted adjusted earnings per share of $0.77, beating the consensus analyst estimate of $0.68 compiled by LSEG. Total quarterly revenue reached $15.03 billion, outpacing expectations and demonstrating momentum in core therapeutic areas beyond pandemic-era vaccines and treatments.
Revenue Growth and Non-COVID Portfolio Performance
The company’s top-line performance relied heavily on established non-COVID medications and recent acquisitions, according to Pfizer’s quarterly report. Core growth drivers included the blood thinner Eliquis, the pneumococcal vaccine Prevnar, and contributions from treatments brought on by the $43 billion acquisition of Seagen completed late last year. According to Pfizer Chief Executive Officer Albert Bourla, the strong performance of the non-COVID portfolio reflects robust underlying demand and successful commercial execution across oncology and specialty care divisions.
Revenue figures contrasted sharply with the prior-year period when pandemic product sales declined steeply from their historical peaks. Market analysts tracked by FactSet noted that non-COVID operational growth exceeded internal company projections, helping offset lingering declines in Comirnaty vaccine sales and Paxlovid distribution revenues.
Net Loss Driven by Asset Impairment and Writedowns
Despite beating top and bottom-line consensus forecasts for operational earnings, Pfizer posted a net loss for the quarter under generally accepted accounting principles. According to the company’s financial filings, the loss was primarily driven by a $4.3 billion non-cash writedown and related charges associated with specific research and development assets and commercial portfolio adjustments.
Chief Financial Officer Dave Denton explained to investors during the earnings call that the impairment charges reflect ongoing portfolio prioritization and pipeline rationalization following the Seagen integration. The financial adjustments account for discontinued programs and revised sales projections for certain acquired clinical-stage compounds, aligning the company’s balance sheet with updated regulatory and market assessments.
Full-Year Guidance and Market Outlook
Following the second-quarter results, Pfizer updated its financial outlook for the full fiscal year 2024. According to corporate guidance issued in the earnings release, management narrowed and raised its adjusted earnings per share guidance range to between $2.15 and $2.35, up from previous projections. The company maintained its full-year revenue guidance range of $58.5 billion to $61.5 billion.
Healthcare equity analysts observing the earnings release noted that the upgraded earnings forecast signals management confidence in cost-containment measures and accelerating operational synergies from the Seagen merger. Execution risks remain, however, particularly regarding upcoming late-stage clinical trial readouts and patent expirations for key legacy blockbusters approaching later this decade.
Worth a look